Literature DB >> 16170485

Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor.

Tanja Fehm1, Holger Maul, Sigrun Gebauer, Alexander Scharf, Peter Baier, Christof Sohn, Wolfram Jäger, Gerhard Gebauer.   

Abstract

BACKGROUND AND
PURPOSE: The increasing use of systemic adjuvant therapy even in lymph node-negative breast cancer patients and breast cancer screening programs detecting smaller tumors with less probability of metastatic lymph nodes questions the need for routine axillary lymph node dissection. Since morbidity of breast cancer surgery is predominantly related to axillary lymph node dissection, predictive models for lymph node involvement may provide a way to avoid lymph node surgery and its side effects in subgroups of patients. PATIENTS AND METHODS: Using a multivariate logistic regression model, tumorbiological parameters such as expression of estrogen and progesterone receptors, Ki-67, p53, cathepsin D, HER2, S-phase fraction, and ploidy were analyzed regarding their ability to predict axillary lymph node involvement in 655 breast cancer patients.
RESULTS: The model correctly predicted axillary lymph node metastases in 58% of the patients by including expression of progesterone receptor, HER2, and Ki-67. In a subgroup of 200 patients predicted to be at extremely high or extremely low risk for axillary lymph node metastases, the accuracy of the prediction was 70%.
CONCLUSION: With a model just based on tumorbiological parameters obtained in the primary tumor it is possible to predict axillary lymph node status. By including additional parameters it appears to be feasible to further improve the model in order to avoid axillary lymph node surgery in low-risk women.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170485     DOI: 10.1007/s00066-005-1374-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  7 in total

1.  Association between molecular subtypes and lymph node status in invasive breast cancer.

Authors:  Chengshuai Si; Yiting Jin; Hongying Wang; Qiang Zou
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients.

Authors:  Henri Wichmann; Antje Güttler; Matthias Bache; Helge Taubert; Martina Vetter; Peter Würl; Hans J Holzhausen; Alexander W Eckert; Matthias Kappler; Dirk Vordermark
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

3.  Mammographic Density and Prediction of Nodal Status in Breast Cancer Patients.

Authors:  C C Hack; L Häberle; K Geisler; R Schulz-Wendtland; A Hartmann; P A Fasching; M Uder; D L Wachter; S M Jud; C R Loehberg; M P Lux; C Rauh; M W Beckmann; K Heusinger
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-02       Impact factor: 2.915

4.  The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma.

Authors:  Fabien Reyal; Roman Rouzier; Berenice Depont-Hazelzet; Marc A Bollet; Jean-Yves Pierga; Severine Alran; Remy J Salmon; Virginie Fourchotte; Anne Vincent-Salomon; Xavier Sastre-Garau; Martine Antoine; Serge Uzan; Brigitte Sigal-Zafrani; Yann De Rycke
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

5.  Development of nomograms to predict axillary lymph node status in breast cancer patients.

Authors:  Kai Chen; Jieqiong Liu; Shunrong Li; Lisa Jacobs
Journal:  BMC Cancer       Date:  2017-08-23       Impact factor: 4.430

6.  Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer using Radiomics Features of DCE-MRI.

Authors:  Xiaoyu Cui; Nian Wang; Yue Zhao; Shuo Chen; Songbai Li; Mingjie Xu; Ruimei Chai
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

7.  The Role of US in Depicting Axillary Metastasis in High-Risk Breast Cancer Patients.

Authors:  Roxana Pintican; Magdalena Maria Duma; Madalina Szep; Diana Feier; Dan Eniu; Iulian Goidescu; Angelica Chiorean
Journal:  J Pers Med       Date:  2021-12-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.